Strategic Shifts and Market Pressures Weigh on Siemens Healthineers

Siemens Healthineers is navigating a period of significant strategic change. While its core divisions continue to show robust growth, the company’s diagnostics unit has emerged as a primary concern. Management is now being compelled to make decisive choices about the future corporate structure, pressured by a softening Chinese market and the threat of new U.S. tariffs.

External Headwinds and Share Price Impact

Investor sentiment is being dampened by factors beyond the company’s internal restructuring. For the 2026 fiscal year, the conglomerate is factoring in potential negative effects of up to €500 million from anticipated U.S. tariffs. Chief Financial Officer Jochen Schmitz has outlined a plan to fully offset these costs over the coming three years. However, the prevailing uncertainty continues to foster caution in the capital markets. This is reflected directly in the stock’s recent performance: shares touched a new 52-week low of €38.51 on Monday, marking a decline of more than 13% since the start of the year.

Diagnostics Division Faces Challenges

The diagnostics segment is currently under notable margin pressure, primarily in the Chinese laboratory market. This is due to volume-based procurement programs and reduced reimbursement rates. For Q1 of the ongoing 2026 fiscal year, reported revenue in China contracted by eleven percent. Company leadership anticipates persistent weakness in the region for the upcoming second quarter, with improvement expected only in the latter half of the year. This projected recovery is tied to stringent cost-reduction measures and the rollout of the new Atellica platform, which has already achieved strong growth of 20 percent in the Americas.

Should investors sell immediately? Or is it worth buying Siemens Healthineers?

Core Strength Fuels Separation Speculation

In contrast, the rest of the corporation presents a much stronger picture. The Imaging and Precision Therapy divisions delivered solid revenue growth of approximately six percent, driving the company’s adjusted EBIT margin up to 15 percent. To prevent the struggling diagnostics unit from further burdening these high-margin businesses, Siemens Healthineers is aggressively advancing the unit’s operational independence. CEO Bernd Montag recently emphasized this autonomy and explicitly left open the question of long-term ownership. Market observers interpret this as a clear signal of a potential future sale or spin-off. The assignment of an Investment-Grade rating by Moody’s is seen as laying the financial groundwork for such a move.

Despite the segment-specific headwinds, management has reaffirmed its full-year outlook, targeting overall revenue growth between five and six percent. New catalysts for the fundamental valuation are expected shortly: Siemens Healthineers plans to present detailed plans for the separation of its diagnostics business early in the second quarter, ahead of the release of operational figures for the past quarter on May 7, 2026.